Atossa Genetics Inc (ATOS) - Total Assets
Based on the latest financial reports, Atossa Genetics Inc (ATOS) holds total assets worth $58.01 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Atossa Genetics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Atossa Genetics Inc - Total Assets Trend (2009–2024)
This chart illustrates how Atossa Genetics Inc's total assets have evolved over time, based on quarterly financial data. Explore Atossa Genetics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Atossa Genetics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Atossa Genetics Inc's total assets of $58.01 Million consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Atossa Genetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ATOS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atossa Genetics Inc's current assets represent 97.4% of total assets in 2024, a decrease from 98.7% in 2009.
- Cash Position: Cash and equivalents constituted 93.0% of total assets in 2024, down from 98.7% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Atossa Genetics Inc Competitors by Total Assets
Key competitors of Atossa Genetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Atossa Genetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.77 | 13.30 | 2.73 |
| Quick Ratio | 6.77 | 13.30 | 2.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $47.45 Million | $71.31 Million | $27.10 Million |
Atossa Genetics Inc - Advanced Valuation Insights
This section examines the relationship between Atossa Genetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -20.6% |
| Total Assets | $76.44 Million |
| Market Capitalization | $17.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Atossa Genetics Inc's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Atossa Genetics Inc's assets decreased by 20.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atossa Genetics Inc (2009–2024)
The table below shows the annual total assets of Atossa Genetics Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $76.44 Million | -20.58% |
| 2023-12-31 | $96.25 Million | -22.08% |
| 2022-12-31 | $123.53 Million | -12.55% |
| 2021-12-31 | $141.26 Million | +229.72% |
| 2020-12-31 | $42.84 Million | +195.46% |
| 2019-12-31 | $14.50 Million | +23.72% |
| 2018-12-31 | $11.72 Million | +43.56% |
| 2017-12-31 | $8.16 Million | +96.99% |
| 2016-12-31 | $4.14 Million | -33.62% |
| 2015-12-31 | $6.24 Million | -46.93% |
| 2014-12-31 | $11.76 Million | -2.04% |
| 2013-12-31 | $12.01 Million | +75.93% |
| 2012-12-31 | $6.83 Million | +122.21% |
| 2011-12-31 | $3.07 Million | +20365.65% |
| 2010-12-31 | $15.01K | -82.44% |
| 2009-12-31 | $85.46K | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more